{"entity":{"id":"nct06460298","kind":"trial","name":"ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer","aka":[],"tldr":"A phase 1/2 trial of ProAgio Dose Levels (DL) 1,2,3,4 in triple-negative breast cancer, run by ProDa BioTech, LLC, now recruiting.","summary":"ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer is a phase 1/2 interventional study registered as NCT06460298 by ProDa BioTech, LLC, with 51 participants planned, started 2024-08-20 and due to reach its primary completion in 2027-07-01. Interventions recorded: ProAgio Dose Levels (DL) 1,2,3,4 and ProAgio Dose Expansion.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06460298","url":"https://clinicaltrials.gov/study/NCT06460298"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06460298","phase":"1/2","setting":"Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an Anti- αvβ3 Integrin Cytotoxin, in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer","sponsor":"ProDa BioTech, LLC","enrolled":51,"outcomes":[]},"route":"/trials/nct06460298/","neighbours":{"cancer":[{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}]}}